On Feb. 9, 2021, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for bamlanivimab and etesevimab administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kilograms [about 88 pounds]) who tested positive for SARS-CoV-2 and who were at high risk for progressing to severe COVID-19.

The authorized use included treatment for those who are 65 years of age or older or who have certain chronic medical conditions.